278 related articles for article (PubMed ID: 32369239)
61. A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.
Biya J; Caramella C; Lindsay CR; Planchard D; Besse B
J Thorac Oncol; 2015 Jun; 10(6):e44-5. PubMed ID: 26001149
[TBL] [Abstract][Full Text] [Related]
62. Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.
Cho BC; Obermannova R; Bearz A; McKeage M; Kim DW; Batra U; Borra G; Orlov S; Kim SW; Geater SL; Postmus PE; Laurie SA; Park K; Yang CT; Ardizzoni A; Bettini AC; de Castro G; Kiertsman F; Chen Z; Lau YY; Viraswami-Appanna K; Passos VQ; Dziadziuszko R
J Thorac Oncol; 2019 Jul; 14(7):1255-1265. PubMed ID: 30851442
[TBL] [Abstract][Full Text] [Related]
63. Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib.
Hotta T; Okimoto T; Hamaguchi M; Tsubata Y; Isobe T
Intern Med; 2020 Jan; 59(2):253-256. PubMed ID: 31534079
[TBL] [Abstract][Full Text] [Related]
64. Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.
De Pas T; Pala L; Catania C; Conforti F
Future Oncol; 2017 Dec; 13(29):2629-2644. PubMed ID: 28891712
[TBL] [Abstract][Full Text] [Related]
65. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
66. Application of time-dependent modeling for the exposure-efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients.
Lau YY; Gu W; Ho YY; Hong Y; Zhang X; Urban P
Cancer Chemother Pharmacol; 2019 Sep; 84(3):501-511. PubMed ID: 31020351
[TBL] [Abstract][Full Text] [Related]
67. Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
Sakashita T; Yanagitani N; Koike S; Low SK; Takagi S; Baba S; Takeuchi K; Nishio M; Fujita N; Katayama R
Cancer Sci; 2022 Nov; 113(11):3888-3900. PubMed ID: 35950895
[TBL] [Abstract][Full Text] [Related]
68. Role and targeting of anaplastic lymphoma kinase in cancer.
Della Corte CM; Viscardi G; Di Liello R; Fasano M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
Mol Cancer; 2018 Feb; 17(1):30. PubMed ID: 29455642
[TBL] [Abstract][Full Text] [Related]
69. Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review.
Facchinetti F; Bordi P; Bini P; Bidin L; Camisa R; Tiseo M
Curr Drug Targets; 2018; 19(14):1649-1656. PubMed ID: 29437006
[TBL] [Abstract][Full Text] [Related]
70. Ceritinib: A primer for pharmacists.
Au TH; Cavalieri CC; Stenehjem DD
J Oncol Pharm Pract; 2017 Dec; 23(8):602-614. PubMed ID: 27738095
[TBL] [Abstract][Full Text] [Related]
71. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
Fischer M; Moreno L; Ziegler DS; Marshall LV; Zwaan CM; Irwin MS; Casanova M; Sabado C; Wulff B; Stegert M; Wang L; Hurtado FK; Branle F; Geoerger B; Schulte JH
Lancet Oncol; 2021 Dec; 22(12):1764-1776. PubMed ID: 34780709
[TBL] [Abstract][Full Text] [Related]
72. Successful treatment with ceritinib after crizotinib induced hepatitis.
Sassier M; Mennecier B; Gschwend A; Rein M; Coquerel A; Humbert X; Alexandre J; Fedrizzi S; Gervais R
Lung Cancer; 2016 May; 95():15-6. PubMed ID: 27040846
[TBL] [Abstract][Full Text] [Related]
73. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.
Hurry M; Zhou ZY; Zhang J; Zhang C; Fan L; Rebeira M; Xie J
J Med Econ; 2016 Oct; 19(10):936-44. PubMed ID: 27149298
[TBL] [Abstract][Full Text] [Related]
74. Ceritinib for the treatment of non-small cell lung cancer.
Landi L; Cappuzzo F
Drugs Today (Barc); 2014 Jul; 50(7):465-73. PubMed ID: 25101329
[TBL] [Abstract][Full Text] [Related]
75. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
Kaczmar J; Mehra R
Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
[TBL] [Abstract][Full Text] [Related]
76. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.
Khozin S; Blumenthal GM; Zhang L; Tang S; Brower M; Fox E; Helms W; Leong R; Song P; Pan Y; Liu Q; Zhao P; Zhao H; Lu D; Tang Z; Al Hakim A; Boyd K; Keegan P; Justice R; Pazdur R
Clin Cancer Res; 2015 Jun; 21(11):2436-9. PubMed ID: 25754348
[TBL] [Abstract][Full Text] [Related]
77. Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
Won B; Mambetsariev I; Salgia R
BMC Cancer; 2016 Aug; 16():568. PubMed ID: 27480287
[TBL] [Abstract][Full Text] [Related]
78. Ceritinib: a Review in ALK-Positive Advanced NSCLC.
Deeks ED
Target Oncol; 2016 Oct; 11(5):693-700. PubMed ID: 27699584
[TBL] [Abstract][Full Text] [Related]
79. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Chow LQM; Barlesi F; Bertino EM; van den Bent MJ; Wakelee HA; Wen PY; Chiu CH; Orlov S; Chiari R; Majem M; McKeage M; Yu CJ; Garrido P; Hurtado FK; Arratia PC; Song Y; Branle F; Shi M; Kim DW
Clin Cancer Res; 2022 Jun; 28(12):2506-2516. PubMed ID: 35091443
[TBL] [Abstract][Full Text] [Related]
80. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
